News & Updates
Filter by Specialty:
RAS inhibitors proven beneficial in HFrEF with advanced kidney disease
Use of renin-angiotensin system (RAS) inhibitors results in improved clinical outcomes in patients with heart failure with reduced ejection fraction (HFrEF) and advanced kidney disease, a study has shown.
RAS inhibitors proven beneficial in HFrEF with advanced kidney disease
06 Jul 2023
CV health tool effectively promotes discussions during routine follow-up in cancer survivors
A novel electronic health record (EHR) clinical decision support tool, otherwise called the AH-HA* tool, was effective in promoting cardiovascular health (CVH) discussions among cancer survivors during routine follow-up. This was the primary result of a clinic-randomized, hybrid effectiveness-implementation trial presented at ASCO 2023.
CV health tool effectively promotes discussions during routine follow-up in cancer survivors
06 Jul 2023
Lazertinib improves PFS vs gefitinib in 1L treatment of EGFR-mutated NSCLC
The third-generation EGFR tyrosine kinase inhibitor (TKI) lazertinib significantly improves progression-free survival (PFS) vs gefitinib in first-line (1L) treatment of patients with EGFR -mutated, locally advanced or metastatic non-small-cell lung cancer (NSCLC) harbouring an exon 19 deletion or exon 21 L858R mutation, results of the phase III LASER301 trial have shown.
Lazertinib improves PFS vs gefitinib in 1L treatment of EGFR-mutated NSCLC
06 Jul 2023
More evidence for COVID-19 vaccine safety in kids
COVID-19 vaccines can be safely administered in children, with a recent study showing that out of the numerous health outcomes monitored in near real time, the safety signal identified was for only myocarditis or pericarditis.
